Our investment in R&D is an important contribution to the combined commitment of the pharmaceutical industry, to usher in novel medical innovations. We have a range of exciting prospects in our pipeline, many of which are significant innovations.
One of our key priorities is continuous improvement in our overall productivity and efficiency to enable us to meet our target of delivering new, medically important and commercially successful medicines, and nutraceutical products.
We also look at all the ways our existing products can be used or improved and to strengthen our in-house capabilities, we continue to set up partnerships with leading academic centres and biotechnology companies.
We are committed not only to delivering top quality science but also to high ethical standards in doing so. Our bioethics policy reflects this commitment and it is widely communicated within the company to ensure that we continue to live up to the standards prescribed.